Body / AbdominalNuclear / MolecularNewsTrainee

18F-Flotufolastat PET/MRI Could Slash Prostate Biopsies by Over 50%

Diagnostic Imaging4d ago

A study reports that 18F-flotufolastat PET/MRI may reduce unnecessary prostate biopsies by more than 50%, potentially sparing patients from invasive procedures. The tracer targets PSMA, offering high specificity for clinically significant cancer. Specific design and validation d…

  • The news report lacks study design, sample size, and statistical metrics; the >50% reduction is a claim without reported confidence interval or p-value.
  • 18F-flotufolastat is a PET tracer that binds PSMA, a protein overexpressed in prostate cancer cells.
  • The finding requires peer-reviewed publication and external validation before clinical adoption.
Read the source

Also covered by

RadPigeon summaries are original and for information only. They are not clinical advice.